Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon Bollag

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
Biochimica Et Biophysica Acta|April 19, 2002
GTPase activating proteins: critical regulators of intracellular signalingShane Donovan, Kevin M Shannon, Gideon Bollag
Current Opinion in Investigational Drugs (London, England : 2000)|February 7, 2004
Raf pathway inhibitors in oncologyGideon Bollag, Scott Freeman, John F Lyons, et al.
Expert Opinion on Therapeutic Targets|November 23, 2005
Phosphodiesterase-4 as a potential drug targetKam Y J Zhang, Prabha N Ibrahim, Sam Gillette, et al.
Nature|February 25, 2010
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFPoulikos I Poulikakos, Chao Zhang, Gideon Bollag, et al.
Nature Reviews. Drug Discovery|October 13, 2012
Vemurafenib: the first drug approved for BRAF-mutant cancerGideon Bollag, James Tsai, Jiazhong Zhang, et al.
Cell Cycle (Georgetown, Tex.)|August 22, 2006
Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disordersChristian P Kratz, Suzanne Schubbert, Gideon Bollag, et al.
Oncoimmunology|May 4, 2016
Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF<sup>V600E</sup> melanomaShin Foong Ngiow, Katrina M Meeth, Kimberley Stannard, et al.
Cancer Research|February 19, 2013
CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancerJingying Xu, Jemima Escamilla, Stephen Mok, et al.
Endocrine-Related Cancer|November 8, 2018
Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancerWei Guan, Junhui Hu, Lu Yang, et al.
BMC Cancer|May 6, 2015
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibitionStephen Mok, Jennifer Tsoi, Richard C Koya, et al.
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
Biochimica Et Biophysica Acta|April 19, 2002
GTPase activating proteins: critical regulators of intracellular signalingShane Donovan, Kevin M Shannon, Gideon Bollag
Current Opinion in Investigational Drugs (London, England : 2000)|February 7, 2004
Raf pathway inhibitors in oncologyGideon Bollag, Scott Freeman, John F Lyons, et al.
Expert Opinion on Therapeutic Targets|November 23, 2005
Phosphodiesterase-4 as a potential drug targetKam Y J Zhang, Prabha N Ibrahim, Sam Gillette, et al.
Nature|February 25, 2010
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFPoulikos I Poulikakos, Chao Zhang, Gideon Bollag, et al.
Nature Reviews. Drug Discovery|October 13, 2012
Vemurafenib: the first drug approved for BRAF-mutant cancerGideon Bollag, James Tsai, Jiazhong Zhang, et al.
Cell Cycle (Georgetown, Tex.)|August 22, 2006
Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disordersChristian P Kratz, Suzanne Schubbert, Gideon Bollag, et al.
Oncoimmunology|May 4, 2016
Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF<sup>V600E</sup> melanomaShin Foong Ngiow, Katrina M Meeth, Kimberley Stannard, et al.
Cancer Research|February 19, 2013
CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancerJingying Xu, Jemima Escamilla, Stephen Mok, et al.
Endocrine-Related Cancer|November 8, 2018
Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancerWei Guan, Junhui Hu, Lu Yang, et al.
BMC Cancer|May 6, 2015
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibitionStephen Mok, Jennifer Tsoi, Richard C Koya, et al.
Pageof 9